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ABSTRACT
Objective: The objective of the present investigation is to prepare zolmitriptan (ZOL) mouth dissolving films (MDFs) and to investigate the influence 
of formulation variables on physicomechanical, chemical, and drug release properties of the prepared MDFs.
Methods: The MDFs were prepared by solvent casting technique using wet film applicator. The impact of hydroxypropyl methylcellulose of different 
viscosity grades (hydroxy propyl methyl cellulose [HPMC] E3, E5, and E15), plasticizers (glycerol and polyethylene glycol [PEG]-400), and solubilizing 
agents (polyvinyl pyrrolidone [PVP K30] and sodium lauryl sulfate [SLS]) on physicomechanical, chemical, and drug release properties were evaluated. 
The MDFs were also characterized by Fourier-transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffractometry studies.
Results: The MDFs prepared were transparent and smooth and showed no recrystallization. The tensile strength of the MDFs increased significantly 
with an increase in polymer viscosities, and about a 2.63-fold increase in tensile strength was observed for HPMC E15 MDFs compared to E3, whereas 
an increase in film thickness resulted in brittle MDFs with low tensile strength. Similar results were observed with percent elongation and folding 
endurance of the MDFs. In vitro, drug release studies indicate that higher film thickness and polymer viscosities delayed the MDF disintegration and, 
in turn, the ZOL release. Addition of PVP K30 and SLS to HPMC E3 formulations resulted in 1.66- and 1.53-fold increase in ZOL release rates.
Conclusion: Overall, F7 formulation showed quicker disintegration (within 11 s) and ZOL release rates (within 180 s) along with good physicomechanical 
properties. These results indicated that the disintegration and drug release of ZOL can be enhanced to a greater extent by optimizing formulation 
variables in MDFs.
Keywords: Formulation variables, Mouth dissolving films, Tensile strength, Wet film applicator, Zolmitriptan.
INTRODUCTION
The design of age-specific dosage forms stays to be a challenging task 
due to the wide range of pharmaceutical and clinical lookouts that must 
be considered in the design of dosage forms [1]. Palatability and ease 
of swallowing are imperative factors that are to be considered during 
the design of dosage forms, especially to pediatrics, who have distinct 
inclinations and swallowing capabilities [2].
Conventional oral drug delivery systems such as tablets and capsules 
may not fulfill the necessities of pediatric and geriatric patients due to 
their differential abilities in swallowing the dosage forms [3,4]. In this 
context, the novel mucosal delivery systems have gained popularity in 
which the mouth dissolving films (MDFs) are the new and novel drug 
delivery systems for the peroral delivery of drugs to overcome patient 
impediments [5], and on contact with saliva, it dissolves within a 
few seconds without the need of the water making them particularly 
suitable for pediatric and geriatric patients [6].
Zolmitriptan (ZOL) is a serotonin agonist used for the treatment of 
migraine [7]. ZOL undergoes hepatic first-pass metabolism, and its 
absolute bioavailability is 40–50% of the administered dose with a half-
life of 2.5–3 h [8]. At present, ZOL is marketed as oral disintegrating 
(ZOMIG-ZMT®) and immediate release tablets (ZOMIG®). Formulation 
of ZOL as MDFs may address the issues of low bioavailability along with 
providing the quicker onset of actions. Hence, keeping in perspective 
of the patient compliance and need of the better therapeutic efficacy 
when compared to the existing marketed formulations, in the present 
investigation, an attempt was made to deliver the ZOL as MDFs. Moreover, 
no work was published so far detailing the influence of formulation 
variables such as film thickness, plasticizers, and polymer viscosities 
on physicomechanical properties such as tensile strength, the percent 
elongation of ZOL MDFs along with thorough evaluation on drug loading 
effect on crystallization, and characterization using photographic, 
differential scanning calorimetry (DSC) and X-ray diffractometry (X-RD) 
studies. Hence, the present investigation was aimed at the formulation 




ZOL was obtained from Mylan Laboratories, Hyderabad. HMPC E3, 
E5, and E15 were obtained from Colorcon Asia Ltd., India. Methanol, 
polyvinyl pyrrolidone (PVP K30), and sodium lauryl sulfate (SLS) were 
purchased from Loba Chemie, Mumbai. Aspartame and pineapple 
flavor were obtained from Darwin Laboratories, Vijayawada. All the 
ingredients of analytical grade were used.
Methods
Preparation of artificial saliva
Accurately weighed quantities of sodium chloride – 0.844 g, potassium 
chloride – 1.2 g, calcium chloride dihydrate – 0.193 g, magnesium 
chloride hexahydrate – 0.111 g, and potassium phosphate dibasic – 
0.342 g were added one by one to 500 mL of distilled water, and then, 
the volume was made up to 1000 mL using the distilled water. The pH 
was adjusted with 0.1N HCl to 5.7 [9].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.32176
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Preparation of ZOL MDFs
Initially, placebo MDFs with different polymers and plasticizers 
were prepared to select a suitable combination that forms films 
with desired mechanical strength and appearance. After selecting 
the possible combinations from the placebo studies, ZOL MDFs were 
prepared as per formula given in Table 1 to a batch size of 5 g. To 
prepare the films, ZOL was dissolved in a mixture of solvents (water 
and methanol) in a beaker, followed by the addition of plasticizers and 
other ingredients under continuous stirring. Finally, the polymer was 
added and mixed thoroughly. The mixture was sonicated for 2 min 
to remove entrapped air bubbles and casted on a glass plate with 
a wet film applicator set at 30 mil (750 µm) and 40 mil (1000 µm) 
thickness. The films were dried at 40°C for 60 min in a hot air oven. 
The dried films were then peeled off from the glass plate and stored 
in a desiccator until use.
Chromatographic conditions for the analysis of ZOL
A HPLC system (Shimadzu) comprising a degasser (DGU-20A3), binary 
pump (LC- 20 AD), autosampler (SIL-20 ACHT), and PDA-detector 
(SPD M20A) was used for the analysis of ZOL. LC solution software was 
used to collect and process the data, and separation was achieved on 
Agilent Eclipse Column C18 (150 mm×4.6 mm, 5 µm). Mobile phase 
consisting of formic acid (0.02% v/v):methanol (78:22 v/v) was used 
at a flow rate of 1 mL/min, and the eluents were monitored at 221 nm. 
The developed method was validated as per ICH guidelines and used for 
the analysis of ZOL.
DSC studies
DSC studies for ZOL and selected ZOL MDFs were carried out using 
DSC (Shimadzu, DSC-60, Japan). Samples weighing 5 mg were sealed in 
aluminum pans and heated from 50 to 400°C at a rate of 10°C per min. 
An empty aluminum pan was used as reference [10].
X-RD studies
The crystallographic properties of ZOL and ZOL MDFs were studied 
using X-RD studies. Studies were performed using X-Ray Diffractometer 
(Shimadzu, XRD-7000, Japan) with Cu-Kα radiation at 40 kV and 30 mA. 
X-Ray diffraction patterns were collected over 2θ range of 10–40° at a 
scan rate of 4° per min. The position and intensities of diffraction peaks 
were considered for the identification of ZOL in different samples [10].
Fourier-transform infrared (FT-IR) studies
The compatibility between ZOL and excipients used in MDFs was 
evaluated using FT-IR studies. Studies were carried out using an 
attenuated total reflectance (ATR)-FTIR spectrometer (Bruker, 
Germany). ATR spectra were measured over the wave number range 
of 4000–500 cm-1 at a resolution of 1.0 cm-1. The powder or film sample 
was simply placed onto the ATR crystal, and the sample spectrum was 
collected [10].
Evaluation of ZOL MDFs
Morphological properties
Properties such as homogeneity, color, transparency, and surface of ZOL 
MDFs were tested visually. All the formulations were stored at room 
temperature (25 ± 2°C) with a relative humidity of approximately 65 ± 
5% and were tested periodically every month for a period of 6 months. 
The films were packed in aluminum foil pouches.
Thickness
The thickness of the film was evaluated using a screw gauge with a 
range of 0–10 mm and revolution 0.001 mm. Anvil of the thickness 
gauge was turned and the film was inserted after making sure that the 
pointer was set to zero. The film was held on the anvil and the reading 
on the dial was noted down [10]. The estimations were carried out in 
triplicate.
ZOL content
Three 1 cm2 films were taken from the top, middle, and bottom areas 
of the film and placed in three individual 10 mL volumetric flasks 
containing 5 mL of distilled water and dissolved. The final volume 
was made up to the mark with distilled water. The samples were then 
suitably diluted with artificial saliva and analyzed by HPLC method for 
ZOL content in MDFs.
Variation of mass
Mass variation among the different batches of the formulations was 
calculated by measuring the mass of 1 cm2 film cut from different places 
of the films [10]. The estimations were carried out in triplicate.
In vitro disintegration studies
In the present investigation, in vitro disintegration studies were carried 
out using two independent methods, namely the drop and Petri dish 
methods [11]. For both the methods, only a small amount of medium 
was needed, so natural conditions could be simulated.
Drop method
MDFs of 1 cm2  were placed on a glass slide and placed planar on a Petri 
dish, and one drop of distilled water was added using a pipette onto the 
MDF. The time taken for the drop to dissolve the film and form a hole in 
it was measured. The estimations were carried out in triplicate.
Petri dish method
In this method, 2 mL of distilled water was placed in a Petri dish and a 
film of 2 × 2 cm2 was placed on the surface of the water, and the time 
required to dissolve the film completely was measured. The estimations 
were carried out in triplicate.
Table 1: Composition of different ZOL MDFs
Formulae (5 g size)
Ingredients (mg) F1* F2* F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
ZOL 100 100 100 100 - - - - - - - -
- - - - 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5
HPMC E3 375 375 375 375 375 375 375 375 - - - -
HPMC E5 - - - - - - - - 375 375 375 -
HPMC E15 - - - - - - - - - - 375
PEG 400^ 25 - 25 - - 25 25 25 25 25 25 25
Glycerol^ - 25 - 25 25 - - - - - - -
PVP K30 - - 2 2 - - 2 - - 2 -
SLS - - - - - - - 2 - - 2 -
Water^ 1730 1730 1728 1728 1767 1767 1765 1765 1767 1765 1765 1765
Pineapple flavor 10 10 10 10 10 10 10 10 10 10 10 10
Aspartame 10 10 10 10 10 10 10 10 10 10 10 10
Methanol^ 2750 2750 2750 2750 2750 2750 2750 2750 2750 2750 2750 2750
*F1 and F2 were also casted with 40 mil thickness and represented as F1 (A) and F2 (A), ^Amount taken based on their density. ZOL: Zolmitriptan, 
MDF: Mouth-dissolving films, HPMC: Hydroxypropyl methylcellulose, PEG: Polyethylene glycol, PVP K30: Polyvinyl pyrrolidone, SLS: Sodium lauryl sulfate
275
Asian J Pharm Clin Res, Vol 12, Issue 4, 2019, 273-279
 Maddela and Nalluri 
Tensile strength
Tensile strength is the maximum stress applied to a point at which the 
film specimen breaks[12]. In the present investigation, a tensile strength 
of MDFs was measured using Mini Tech Tensiometer-UTM9051 (Dak 
Systems Inc., Mumbai, India) fitted with a load cell of 500N (50 kg) 
capacity and the data were collected using Test Bench II software. 
MDFs of appropriate thickness with fixed dimensions (LxW-10 cm × 
2 cm) were fixed between pneumatic grips with a gauge dimension of 
3 cm length between grips. All the dimensions were entered into the 
software to calculate the cross-sectional area. The MDF was carefully 
placed in between the pneumatic grips without any loose folds. The 
instrument was operated at a speed of 5 mm/min until the film breaks. 
The whole experiment was carried out in triplicate.
Percentage elongation
In the present study, percentage elongation was computed form 
TestBench-II software during the tensile strength experiments. The 
estimations were carried out in triplicate.
Folding endurance
Folding endurance is determined by repeated folding of the film at 
the same place until the film breaks. This gives an indication of the 
brittleness of the film. The number of times the film is folded without 
breaking is computed as the folding endurance value [13]. The 
estimations were carried out in triplicate.
In vitro drug release studies
The in vitro drug release studies were conducted using 500 mL of 
artificial saliva as dissolution medium using USP Type V dissolution 
rate testing apparatus [14]. A temperature of 37°C and 50 rpm were 
maintained. Each film of appropriate size (3 × 2.4 cm2) equivalent to 
5 mg dose was cut and placed on a watch glass covered with Nylon 
Wire Mesh. The watch glass was then dropped into dissolution flask. 
Samples were withdrawn at predetermined time intervals and every 
time replaced with 2 mL of fresh dissolution medium. The samples 
were analyzed by RP-HPLC-PDA method. The dissolution experiments 
were conducted in triplicate.
Stability studies
Stability studies were carried out on F7 containing 1.25% w/w ZOL 
and hydroxypropyl methylcellulose (HPMC) E3. MDFs were packed in 
aluminum pouches, sealed, and stored at 40 ± 2°C and 75 ± 5% RH for 
6 months. The appearance, weight, and drug content properties of the 
MDFs were examined.
Statistical analysis
The results of experimental data were subjected to one-way ANOVA 
(using Fisher’s LSD post hoc test) using SYSTAT software (SYSTAT 
Software Inc., San Jose, USA). The results with p<0.05 were considered 
as of significant variance.
RESULTS AND DISCUSSION
In the present investigation, the MDFs were prepared using different 
film-forming agents, plasticizers, and different thickness and drug 
loads to study the effect of these variables on physicomechanical and 
drug release properties of MDFs. MDFs were prepared using Wet Film 
Applicator technique to ensure uniformity in film thickness throughout 
the whole area of films.
Preparation of ZOL MDFs
Initially, placebo MDFs were prepared with different polymers such 
as HPMC (E3, E5, and E15) methylcellulose, sodium carboxymethyl 
cellulose (Na CMC), and sodium alginate using polyethylene glycol 
(PEG)-400 and glycerol as plasticizers and assessed for film forming 
capacities and appearance. Methylcellulose and sodium alginate showed 
poor film-forming capacities with MDFs not easily separable from glass 
plate after casting, whereas MDFs prepared using Na CMC and HPMC 
polymers were clear with good mechanical properties. Therefore, Na 
CMC and HPMC were selected for further development. However, on 
drug loading, crystallization of ZOL was observed immediately with 
MDFs prepared using Na CMC. Besides, the MDFs were brittle and were 
not easily separable from the glass plate, whereas MDFs prepared with 
HPMC polymers were transparent and elegant in appearance with 
quick-drying rates and good mechanical properties. Hence, HPMC 
polymers with three viscosity grades (E3, E5, and E15) were selected 
for the development of ZOL MDFs. Different ZOL MDFs were prepared 
as per the formulae given in Table 1. A 5 g batch size of formulations 
gave approximately 90 cm2 film area.
Morphological properties
MDFs were visually tested for homogeneity, transparency, color, and 
smoothness. MDFs formulated with 2% w/w ZOL load were transparent 
initially but turned opaque within 10 days, which might be due to 
recrystallization of ZOL within the MDFs. To prevent the crystallization, 
PVP K30 as a solubilizing agent was added to formulations at 
0.04%w/w level. However, crystallization of ZOL was still observed, 
and hence, further trails were made by decreasing the ZOL load to 
1.25%w/w. MDFs with 1.25%w/w ZOL load were clear and transparent 
with no crystallization even at the end of 6months. Hence, ZOL load of 
1.25%w/w was chosen for further development. The photographs of 
ZOL MDFs with 2 and 1.25%w/w drug loads are shown in Fig. 1. The 
morphological characterization of MDFs was further established by 
visualizing MDFs under a binocular microscope (Olympus-CH20i) with 
magnification ×10. The photomicrographs of MDFs are shown in Fig. 2.
DSC studies
Crystallization of ZOL within the MDFs was further evaluated by DSC 
studies. DSC thermograms obtained for ZOL and selected ZOL MDFs 
(F6 and F7) are shown in Fig. 3. Thermogram of ZOL showed a solitary 
sharp melting endothermic peak at 141.6°C, indicating that ZOL exists 
in a single crystalline state. Thermograms of ZOL MDFs demonstrate 
no or weak peak signals compared to pure ZOL, and it might be due to 
Fig. 2: Photomicrographs of (a) (zolmitriptan), (b) (F1), (c) (F6)
cba
Fig. 1: Photographs of ZOL MDFS with 2%w/w (F1 and F2) and 
1.25%w/w (F6, F9, and F12) ZOL loads. (Coloring agent was not 
added to show the difference in appearance between crystallized 
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molecular dispersion of ZOL within the MDFs. Furthermore, no extra 
peaks were observed in the thermograms indicating the absence of 
recrystallization of ZOL within the MDFs.
X-RD studies
ZOL and selected ZOL MDFs (F6 and F7) were subjected to X-RD studies 
to gain deeper insights into the crystallographic properties of ZOL in 
MDFs. ZOL demonstrated characteristic peaks at 19°, 21.70°, 23.65°, 
and 37.82°2θ. The X-ray diffractograms of the ZOL MDFs (Fig. 4.) 
showed weak or no signals when compared to the characteristic peaks 
of ZOL. Overall, together with DSC data, the X-RD results clearly indicate 
that the ZOL was not in a crystalline state in MDFs.
FT-IR studies
The compatibility of ZOL with different excipients used in the 
formulation was evaluated using FT-IR studies, and FT-IR spectra of ZOL 
and MDFs (F7) are shown in Fig. 5. ZOL showed characteristic peaks 
at 3350 cm-1 (aromatic secondary amine N-H stretching), 2974 cm-1 
(aromatic C-H stretching), 1736 cm-1 (C = O 5 member cyclic stretching), 
and 1259 cm-1 (C-N aliphatic amine stretching) wavenumbers. All these 
characteristic peaks of ZOL were retained in the MDFs and no shift 
in major peaks was observed, indicating that there is no interaction 
between ZOL and excipients in MDFs.
Thickness
The thickness of the MDFs was measured with screw gauge at 
different places of the whole film to evaluate the reproducibility of 
the preparation method. Around 90% of wet film thickness was lost 
during drying. Preparation of MDFs with wet film applicator brought 
in uniform thickness throughout the whole area of film (p>0.05). The 
results are given in Table 2. MDFs casted at 40 mil showed higher 
thickness (100.00 ± 0.00µm and 108.33 ± 4.08 µm, respectively, for 
F1 A and F2 A) compared to MDFs casted at 30 mil (70.00 ± 0.00 µm 
and 78.33 ± 4.08 µm, respectively, for F1 and F 2). Among the polymers 
used, MDFs with HPMC E15 as film former showed higher thickness 
(88.33 ± 4.08 µm) compared to HMPC E3 (68.33 ± 4.08 µm) and 
E5 (78.33 ± 4.08 µm). Higher polymer viscosity as in the case with 
E15 resulted in lesser film area and subsequently MDFs with higher 
thickness.
ZOL content
Films of 1 cm2 were cut from different places (n=3) of the MDF, and 
ZOL content was estimated. The results are given in Table 2. The results 
indicated a good uniformity of ZOL within the film (p>0.05), and overall 
good solubilization of ZOL in MDFs was observed. MDFs casted at 40 
mil thickness gave higher ZOL content values (1.30 ± 0.05 mg/cm2 and 
1.39 ± 0.05 mg/cm2, respectively, for F1A and F2A) compared to MDFs 
casted at 30 mil thickness (1.09 ± 0.01 mg/cm2 and 1.18 ± 0.02 mg/cm2, 
respectively, for F1 and F2), which may be due to decrease in film area 
resulting in more drug entrapment within the small area of the film.
Variation of mass
Mass of 1 cm2 films cut from different batches was recorded on an 
electronic balance (Shimadzu-ATX224), and the results are given 
in Table 2. The same mass was obtained with three batches of films 
(p>0.05) indicating reproducibility of preparation method and 
formulation.
In vitro disintegration studies
In the present investigation, disintegration time was assessed by drop 
and Petri dish methods, and the results are given in Table 2. From the 
results, it was found that thickness of films, polymer viscosities, and 
presence of solubilizing agents had affected the disintegration times 
of MDFs. A 2.82-fold decrease in disintegration times was observed 
Fig. 3: Differential scanning calorimetry thermograms of 
Zolmitriptan (A), F6 (B), and F7 (C)
Fig. 4: X-ray diffractometry spectra of zolmitriptan (A), F6 (B) and 
F7 (C)
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with MDFs casted at 30 mil thickness compared to 40 mil films. Faster 
disintegration of 30 mil films can be attributed to lesser film thickness 
compared to 40 mil films. The results also indicate that an increase 
in polymer viscosity delayed the disintegration of MDFs. HPMC E15 
formulations showed significantly slower disintegration times (p<0.05) 
compared to E5 and E3 formulations. Addition of PVP K30 and SLS as 
solubilizing agents to formulations resulted in faster disintegration of 
MDFs, and about 2.09- and 1.81-fold decrease in disintegration times 
was observed for PVP and SLS formulations, respectively, compared to 
MDFs without them. The images of MDF (F7) disintegration by drop 
and Petri dish methods are shown in Fig. 6a and b, respectively.
Tensile strength and percentage elongation
In the present investigation, the effect of polymer viscosities, film 
thickness, plasticizers, and solubilizing agents on mechanical properties 
of ZOL MDFs was studied. The tensile strength of MDFs was measured 
using Mini Tech Tensiometer-UTM9051 and the tensile strength profiles 
are shown in Fig. 7. From the results obtained, it was found that MDFs 
casted at 40 mil showed low tensile strength compared to MDFs of 30 
mil thickness showing the inverse relation between tensile strength 
and film thickness (Fig. 7a). Formulations prepared with HPMC E15 
showed higher tensile strength compared to E5 and E3, indicating 
that an increase in polymer viscosity resulted in an increase in tensile 
strength of the films (Fig. 7c). MDFs with glycerol as plasticizer showed 
low tensile strength values compared to MDFs with PEG-400 (Fig. 7b). 
No significant difference in tensile strength of MDFs was observed with 
the addition of solubilizing agents to the formulations.
Percentage elongation of films was computed form TestBench-II software 
during tensile strength measurements and the results are given in 
Table 2. MDFs casted at 40 mil thickness (F1A) showed less percentage 
elongation (47.36 ± 2.72) compared 30 mil films (F1, 89.50 ± 0.77). 
Among the different polymers used, higher percentage elongation was 
obtained with HPMC E15 films (F12, 95.04 ± 0.07) compared to E3 
(F6, 74.60 ± 0.69) and E5 (F9, 80.14 ± 0.24) films. Films prepared with 
PEG-400 as a plasticizer (F1) showed higher percentage elongation 
values (89.50 ± 0.77) compared to films prepared with glycerol 
(F2, 67.30 ± 1.92). Overall, from the results, it can be inferred that polymer 
viscosities, plasticizers, and film thickness have a significant impact on 
the mechanical properties of MDFs [15]. MDFs with glycerol as plasticizer 
and MDFs casted at 40 mil thickness were brittle with poor mechanical 
properties compared to other formulations. Overall, MDFs prepared with 
HPMC E3 containing PEG 400 as plasticizer casted at 30mil thickness 
showed moderate tensile strength and high percentage elongation.
Folding endurance
Along with tensile strength, folding endurance demonstrates the 
resistance of film toward mechanical forces during packing or transport. 
MDFs prepared with glycerol and MDFs casted at 40 mil thickness 
showed low folding endurance values compared to other formulations. 
The results are shown in Table 2.
In vitro drug release studies
In the present investigation, ZOL release from MDFs was evaluated using 
USP Type-V dissolution rate testing apparatus. 500 mL of artificial saliva 
was used as dissolution medium to mimic the in vivo conditions. The 
Table 2: Physicomechanical and chemical properties of ZOL MDFs
Formulations ZOL content*
(mg/cm2)
Thickness* (µm) Mass variation* (mg) % Elongation Folding 
endurance*
Disintegration time* (s)
Drop method Petri dish method
F1 1.09±0.01 70.00±0.00 4.06±0.05 89.50±0.77 106±0.58 21.33±0.58 30.00±0.00
F1(A) 1.30±0.05 100.00±0.00 5.48±0.46 47.36±2.72 34±1.53 60.33±0.58 82.33±0.58
F2 1.18±0.02 78.33±4.08 4.35±0.30 67.30±1.92 74±1.53 17.33±1.73 27.67±0.58
F2(A) 1.39±0.02 108.33±4.08 5.67±0.58 33.44±1.16 16±1.15 50.67±2.31 75.67±0.58
F3 1.06±0.08 71.67±4.08 4.11±0.08 92.96±0.90 109±1.00 12.00±0.00 24.00±1.00
F4 1.08±0.05 81.67±4.08 4.78±0.33 69.16±1.47 78±1.53 11.00±0.00 22.33±0.58
F5 0.75±0.00 81.67±4.08 4.67±0.21 65.69±0.29 72±1.15 17.67±0.58 28.67±1.15
F6 0.70±0.01 68.33±4.08 3.52±0.36 74.60±0.69 108±1.53 23.00±0.00 32.33±0.58
F7 0.75±0.02 70.00±0.00 4.00±0.00 99.68±0.77 115±1.73 11.00±0.00 24.67±0.58
F8 0.76±0.02 70.00±0.00 4.00±0.00 97.36±0.32 114±0.58 12.66±0.58 26.00±0.00
F9 0.71±0.00 78.33±4.08 4.32±0.17 80.14±0.24 92±0.58 28.00±0.00 38.00±0.00
F10 0.76±0.03 80.00±0.00 4.35±0.29 76.18±0.31 86±1.15 18.67±0.58 34.00±0.00
F11 0.75±0.02 80.00±0.00 4.41±0.09 72.70±0.69 82±2.25 20.00±0.00 35.00±0.00
F12 0.79±0.01 88.33±4.08 4.95±0.06 95.04±0.07 88±1.00 33.33±0.58 42.67±0.58
* Values represented are mean±SD (n=3). ZOL: Zolmitriptan, MDF: Mouth dissolving films, SD: Standard deviation
Fig. 7: Effect of film thicknesses (a), plasticizers (b) and polymer 
viscosities (c) on tensile strength of films
c
ba
Fig. 6: In vitro disintegration of ZOL MDFS (F7) by drop method 
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effect of various formulation variables such as thickness, plasticizers, 
polymer viscosities, and solubilizing agents on ZOL release from MDFs 
was studied.
Initially, to study the influence of plasticizers and film thickness on ZOL 
release rates from MDFs, formulations were prepared using HPMC E3 
as film-forming agent, PEG-400, and glycerol as plasticizers and casted 
at 30 and 40 mil thickness. The cumulative percentage ZOL released at 
the end of 5 s is 5.62 ± 0.95, 3.50 ± 0.42, 3.91 ± 0.15, and 3.60 ± 0.21 
for F1, F1 (A), F2, and F2 (A), respectively. Complete ZOL release was 
obtained at 300 s and 240 s for F1 and F2, respectively, whereas F1 
(A) showed only 67.13 ± 0.56% release at the end of 300 s and F2 (A) 
showed only 56.9 ± 1.93% ZOL release at the end of 240 s (Fig. 8a).
The ZOL release from MDFs casted at 30 mil thickness was significantly 
higher (p<0.05) when compared to MDFs of 40 mil thickness. The 
higher film thickness resulted in more time being taken by the films to 
disintegrate and hence resulted in slower ZOL release from MDFs [16]. 
Hence, a film thickness of 30 mil was selected for further formulation 
studies. Among the plasticizers used, formulations with glycerol showed 
slightly faster ZOL release compared to the formulation containing 
PEG 400. However, PEG 400 was selected as a plasticizer for further 
development based on its superior mechanical properties compared to 
glycerol.
Studies were continued to evaluate the effect of polymers viscosities 
on ZOL release from MDFs. Formulations were prepared with 30 mil 
thickness using PEG-400 as a plasticizer and HPMC E3, E5, and E15 
as film formers. The cumulative percentage ZOL released at the end 
of 5 s is 17.64 ± 1.20, 15.62 ± 0.71 and 10.61 ± 0.36 for F6, F9, and 
F12, respectively. Complete ZOL release was obtained at 300, 420, 
and 600 s, respectively (Fig. 8b). The ZOL release from F6 (only E3) is 
significantly higher (p<0.05) when compared to F9 (only E5) and F12 
(only E15). Faster ZOL release rates observed with HPMC E3 polymer 
can be attributed to the low viscosity of E3 compared to E5 and E15. 
Overall, the order of percentage ZOL release from MDFs was found to 
be F6>F9>F12.
Further, the effect of solubilizing agents on ZOL release rates was also 
studied. Both PVP K30 and SLS were added to formulations at 0.04% 
level. The cumulative percent ZOL release at the end of 5s for MDFs 
with PVP K30 (F7) and SLS (F8) was 23.03 ± 0.86 and 23.16 ± 0.59, 
respectively (Fig. 8b). Complete ZOL release was obtained at 180 s 
for both the formulations. Addition of solubilizing agents resulted in 
faster ZOL release rates and about a 1.66- and 1.53-fold increase in 
ZOL release rates was obtained for F7 and F8, respectively, compared 
to MDFs without them.
Overall, from the in vitro drug release studies, it can be concluded 
that film thickness, polymer viscosities, and solubilising agents had 
a significant impact on ZOL release from MDFs [16]. Among the 
formulations prepared, F7 formulation showed superior ZOL release 
rates along with good physicomechanical properties compared to 
remaining formulation
Drug release kinetics
To better understand the release profiles obtained with ZOL MDFs 
formulations, the drug release data obtained at different time points 
were fitted into kinetic models such as first order [17] and Higuchi 
model [18].
The first-order release rate constant “k” (s−1) values were higher for 
F1 (0.011 s−1) and F2 (0.011 s−1) compared to F1 (A) (0.005 s−1) and 
F2 (A) (0.004 s−1), respectively. A 2.2- and 2.75-fold increase in “k” 
values was observed for F1 and F2 with that of F1 (A) and F2 (A). The 
“k” values were higher for HPMC E3 (F6) formulations compared to 
E5 (F9) and E15 (F12) formulations. A 1.36- and 1.66-fold increase in 
“k” values was obtained for F6 (0.015 s−1) compared to F9 (0.011 s−1) 
and F12 (0.009 s−1). When compared to F6 (only E3), the first-order 
release rate constant “k” values were significantly higher for F7 and 
F8 containing PVP K 30 and SLS. A 1.66- and 1.53-fold increase in 
“k” values for F7 (0.025 s−1) and F8 (0.023 s−1) was observed when 
compared to F6. The Higuchi square root model of all MDFs showed 
higher correlation coefficient values (0.899–0.993) indicating diffusion 
as a release mechanism.
Stability studies
Stability studies were carried out for F7 formulation containing 
1.25% w/w ZOL with HPMC E3 and PVP K30. MDFs were stored at 40 ± 
2°C with a relative humidity of 75 ± 5% for 6 months. The appearance, 
weight variation, and drug content of the MDFs were examined. The 
appearance of MDFs remained unchanged throughout the studies, and 
no crystallization was observed. There is no statistically significant 
change (p>0.05) observed in weight of MDFs. F7 showed 95–99% of 
ZOL content after 6 months, indicating that the ZOL was stable in MDFs.
CONCLUSION
From this investigation, it can be concluded that ZOL can be successfully 
formulated as MDFs. From the results, it was observed that film 
thickness and plasticizers had a significant impact on the mechanical 
properties of MDFs. In addition, polymer viscosity was found to play 
a crucial role in ZOL release rates along with the physicomechanical 
properties. Faster drug release rates obtained from MDFs may provide a 
quick onset of action with enhanced oral bioavailability and therapeutic 
efficacy compared to current marketed formulations such as IR and 
ODTs.
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